Skip to content
DraconiticResearch
Search Sources API
190,839 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BYBJUI compass

The impact of 5‐alpha reductase inhibitors on multiparametric MRI diagnostic performance and prostate‐specific antigen density triage: A systematic review

  • Gregory Harrison1
  • Bogdan Toia2
  • Anju Sahdev1,3
  • Prabhakar Rajan3,4,5
  • Benjamin W. Lamb3,4,5,6
6 affiliations
  1. 1Department of Urology Whittington Health NHS Trust London UK
  2. 2Department of Urology University College London Hospitals (UCLH) NHS Foundation Trust London UK
  3. 3Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute Queen Mary University of London London UK
  4. 4Department of Urology Barts Health NHS Trust London UK
  5. 5Department of Urology University College London Hospitals NHS Foundation Trust London UK
  6. 6North East London Cancer Alliance NHS North East London London UK
Read full textPDFDOICite

Abstract

Objectives: To evaluate the impact of 5‐alpha reductase inhibitor (5‐ARI) exposure on multiparametric MRI (mpMRI) diagnostic performance for clinically significant prostate cancer (csPCa) and to assess whether standard prostate‐specific antigen density (PSAD)‐gated biopsy thresholds remain safe in this population.

Subjects/patients and methods: A systematic review followed PRISMA 2020 (PROSPERO: CRD420251050507). PubMed/MEDLINE, EMBASE and the Cochrane Library were searched from January 2015 to December 2024. Eligible studies reported PI‐RADS, PSAD or lesion‐level apparent diffusion coefficient (ADC) data by exposure status, biopsy‐verified csPCa (ISUP grade group ≥2) and an unexposed comparator (≥100 patients). Risk of bias was assessed using QUADAS‐2 and ROBINS‐I; heterogeneity precluded meta‐analysis.

Results: Seven comparative studies met inclusion criteria. Patient‐level csPCa diagnostic accuracy was largely maintained: Sensitivity at a PI‐RADS ≥3 threshold was 93.8% in exposed versus 96.1% in unexposed men, csPCa detection was 39.1% versus 39.3% (p = 0.9), and 5‐ARI exposure was not an independent negative predictor of detection. On blinded matched review, peripheral zone lesion ADC was higher in exposed men (869 vs. 765 mm2/s, p = 0.04) with lower conspicuity (1.59 vs. 1.78, p = 0.03); that cohort also reported lower adjusted per‐lesion yield (OR 0.32, 95% CI 0.18–0.57), confined to the peripheral zone. A PSAD threshold of >0.15 ng/ml/cc avoided biopsy in 37.0% of exposed versus 30.3% of unexposed men, with missed csPCa in 12.3% and 11.0%, respectively.

Conclusion: Across seven heterogeneous observational studies, patient‐level mpMRI performance for csPCa appears largely preserved in men receiving 5‐ARIs, though this lacks pooled support and was not reproduced in the one lesion‐level, zone‐stratified analysis. Standard PSAD‐gated thresholds, evidenced by a single cohort, may perform comparably across populations. Prospective validation is required.

Related

  1. 5-α-reductase inhibitors and the risk of suicide and neuropsychiatric symptoms: a meta-analysis of observational studies
    Federica Fraenza, Valerio Liguori, Ciro Pentella +4
    Frontiers in urologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. From underdiagnosis to scalable screening: Applications of artificial intelligence for vertebral compression fracture detection – a systematic review and meta-analysis of diagnostic performance
    Hsuan-Yu Chen, Linjun Yang, Gwen Wilson +4
    Osteoporosis and sarcopeniaPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Diagnostic Accuracy of Multiparametric Ultrasound Versus Cross-Sectional Imaging for Differentiating Benign and Malignant Cervical Lymph Nodes: A Histopathology-Referenced Retrospective Study
    Inva Muçi, Steffen Dommerich, Philipp Arens +5
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Diagnostic value of a multiparametric magnetic resonance imaging-based nomogram incorporating apparent diffusion coefficient in preoperative differentiation of phyllodes tumors from breast cancer: a retrospective study
    Zifan Wei, Hanyan Hu, Yunshu Dai +6
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  5. The relationship between 5α-reductase inhibitors and the presence of following open angle glaucoma: a TriNetX cohort study.
    Chia-Yi Lee, Shun-Fa Yang, Shih-Chi Su +5
    International journal of medical sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{harrison2026impact,
  title = {{The impact of 5‐alpha reductase inhibitors on multiparametric MRI diagnostic performance and prostate‐specific antigen density triage: A systematic review}},
  author = {Gregory Harrison and Bogdan Toia and Anju Sahdev and Prabhakar Rajan and Benjamin W. Lamb},
  journal = {BJUI compass},
  year = {2026},
  month = oct,
  doi = {10.1002/bco2.70294},
  url = {https://europepmc.org/article/PMC/PMC13722573},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The impact of 5‐alpha reductase inhibitors on multiparametric MRI diagnostic performance and prostate‐specific antigen density triage: A systematic review
AU  - Gregory Harrison
AU  - Bogdan Toia
AU  - Anju Sahdev
AU  - Prabhakar Rajan
AU  - Benjamin W. Lamb
PY  - 2026
DA  - 2026/10/30
JO  - BJUI compass
DO  - 10.1002/bco2.70294
UR  - https://europepmc.org/article/PMC/PMC13722573
AB  - Objectives: To evaluate the impact of 5‐alpha reductase inhibitor (5‐ARI) exposure on multiparametric MRI (mpMRI) diagnostic performance for clinically significant prostate cancer (csPCa) and to assess whether standard prostate‐specific antigen density (PSAD)‐gated biopsy thresholds remain safe in this population.  Subjects/patients and methods: A systematic review followed PRISMA 2020 (PROSPERO: CRD420251050507). PubMed/MEDLINE, EMBASE and the Cochrane Library were searched from January 2015 to December 2024. Eligible studies reported PI‐RADS, PSAD or lesion‐level apparent diffusion coefficient (ADC) data by exposure status, biopsy‐verified csPCa (ISUP grade group ≥2) and an unexposed comparator (≥100 patients). Risk of bias was assessed using QUADAS‐2 and ROBINS‐I; heterogeneity precluded meta‐analysis.  Results: Seven comparative studies met inclusion criteria. Patient‐level csPCa diagnostic accuracy was largely maintained: Sensitivity at a PI‐RADS ≥3 threshold was 93.8% in exposed versus 96.1% in unexposed men, csPCa detection was 39.1% versus 39.3% (p = 0.9), and 5‐ARI exposure was not an independent negative predictor of detection. On blinded matched review, peripheral zone lesion ADC was higher in exposed men (869 vs. 765 mm2/s, p = 0.04) with lower conspicuity (1.59 vs. 1.78, p = 0.03); that cohort also reported lower adjusted per‐lesion yield (OR 0.32, 95% CI 0.18–0.57), confined to the peripheral zone. A PSAD threshold of >0.15 ng/ml/cc avoided biopsy in 37.0% of exposed versus 30.3% of unexposed men, with missed csPCa in 12.3% and 11.0%, respectively.  Conclusion: Across seven heterogeneous observational studies, patient‐level mpMRI performance for csPCa appears largely preserved in men receiving 5‐ARIs, though this lacks pooled support and was not reproduced in the one lesion‐level, zone‐stratified analysis. Standard PSAD‐gated thresholds, evidenced by a single cohort, may perform comparably across populations. Prospective validation is required.
SN  - 2688-4526
ER  -